US37733W2044 - ADR - After market: 35.3599 +0.06 (+0.17%)
NYSE:GSK (1/27/2023, 7:11:53 PM)-0.04 (-0.11%)
GICS Sector | Health Care | ||
GICS Industry | Pharmaceuticals |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-02 2022-11-02/bmo | Earnings (Next) | 02-01 2023-02-01 |
Ins Owners | N/A | Inst Owners | 0.56% |
Market Cap | 72.26B | Shares | 2.05B |
PE | 9.27 | Fwd PE | 9.63 |
Dividend Yield | 7.11% | Analysts | 70 |
IPO | 05-22 1972-05-22 |
Find more stocks on New York Stock Exchange, Inc.
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 90,096 full-time employees. The firm makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. The company develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. The company has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions, including the chronic autoimmune condition lupus, respiratory disease, and human immunodeficiency virus (HIV). Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics and medicines for skin diseases. The company has a global network of about 12 vaccines manufacturing sites.
GSK PLC-SPON ADR
980 Great West Road
Brentford MIDDLESEX TW8 9GS
P: 442080475000.0
CEO: Emma Walmsley
Employees: 90096
Website: https://www.gsk.com/
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future.
These low-priced equities could deliver enormous returns for risk-tolerant shareholders.
Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market.
Microsoft and Google are slashing jobs. Netflix and Tesla jumped.
After years of lab failures, the companies could crack open a multibillion-dollar market.
Moderna (MRNA) added ~8% in early trading Wednesday as Bank of America welcomed the company's Phase 3 data for mRNA-1345, its respiratory syncytial virus vaccine. Read the full story here.
Here you can normally see the latest stock twits on GSK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: